Skip to main content
. 2020 Apr 1;27(Suppl 2):S78–S86. doi: 10.3747/co.27.5183

TABLE I.

Immune checkpoint inhibitors with reported phase III trial results for lung cancer

Agent Target
Ipilimumab CTLA-4
Nivolumab PD-1
Pembrolizumab PD-1
Atezolizumab PD-L1
Durvalumab PD-L1
Avelumab PD-L1

CTLA-4 = cytotoxic T lymphocyte–associated protein 4; PD-1 = programmed cell death 1; PD-L1 = programmed cell death ligand 1.